NCT02023359View on ClinicalTrials.gov

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Breast Cancer
Interventions
DRUG

Everolimus and exemestane

Trial Locations (3)

6700

Onkologisk Afdelning, SVS Esbjerg, Esbjerg

9000

Aalborg Universitetshospital, Clinical Research unit Department of oncology, Klinik Kirurgi-kræft, Hobrovej 18-22, Aalborg

Unknown

Department of Oncology, Odense University Hospital, Odense

Sponsors
All Listed Sponsors
lead

Novartis Healthcare A/S

INDUSTRY

NCT02023359 - Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter